Fundraising Fox
Climb Bio
NASDAQ: CLYM2 known investors
Find your way into Climb Bio
Sign up to see every warm intro you have to Climb Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Climb Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.
Founders & leadership
AL
AB
Aoife Brennan, MB, ChBPresident and Chief Executive Officer
PW
Perrin Wilson, PhDChief Business Officer
SA
Susan Altschuller, PhD, MBAChief Financial Officer
EC
Edgar Charles, MDChief Medical Officer
AJ
Ashley JonesSenior Vice President, People & Workforce StrategySenior Vice President of People & Workforce Strategy at Climb Bio, a clinical-stage biotech company developing monoclonal antibody therapies for immune-mediated diseases.
AV
Adam Villa, MBA, MSSenior Vice President, Technical Operations
CA
Chandra Adams, JDSenior Vice President, General Counsel
Investors · 2
RA Capitallisted by RA CapitalBoston
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
Valuation · disclosed
Disclosed events$317Mvaluation at IPOAug 2021 · $12.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Climb Bio went on to found or lead other companies.
Frequently asked questions
- What does Climb Bio do?
- Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.
- Who founded Climb Bio?
- Climb Bio was founded by Andrew Levin.
- Who are Climb Bio's investors?
- Climb Bio's investors include LifeArc Ventures, RA Capital.